Do you want to read an article? Please log in or register.
Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib
Pulmonary Fibrosis
RECOMMENDED
Related content
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
N Engl J Med.
Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators
doi: 10.1056/NEJMoa1811737.
RECOMMENDED
Pulmonary Fibrosis
Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA, IPF-PRO™ Registry investigators.
doi: 10.1016/j.chest.2019.12.041.
Pulmonary Fibrosis
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
Lancet Respir Med.
Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG, INMARK trial investigators.
doi: 10.1016/S2213-2600(19)30255-3.
RECOMMENDED
Pulmonary Fibrosis
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ
doi: 10.1186/s12931-020-1315-4.
RECOMMENDED
Pulmonary Fibrosis
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Kreuter M, Wuyts WA, Wijsenbeek M, Bajwah S, Maher TM, Stowasser S, Male N, Stansen W, Schoof N, Orsatti L, Swigris J
doi: 10.1186/s12931-020-1298-1.
RECOMMENDED
Pulmonary Fibrosis
Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, Kimman ML, Wijsenbeek MS
doi: 10.1186/s12931-020-01458-1.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respirology
Durheim MT, Bendstrup E, Carlson L, Sutinen EM, Hyldgaard C, Kalafatis D, Myllärniemi M, Sköld CM, Sjåheim T
doi: 10.1111/resp.14116
RECOMMENDED
Pulmonary Fibrosis
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J.
Sakamoto S, Kataoka K, Kondo Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saito T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S, Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan
doi: 10.1183/13993003.00348-2020.